Cerebral blood flow in patients with congestive heart failure treated with captopril

doi:10.1016/0002-9343(84)90892-1

The American Journal of Medicine

Volume 76, Issue 5, Part B, 31 May 1984, Pages 91-95

https://doi.org/10.1016/0002-9343(84)90892-1 Get rights and content

Abstract

The effect of captopril on cerebral blood flow was studied in five patients with severe congestive heart failure and in five control subjects. Cerebral blood flow was measured by inhalation of ¹³³xenon and registration of its uptake and washout from the brain by single photon emission computer tomography. In addition, cerebral (internal jugular) venous oxygen tension was determined in the controls. The measurements were made before and 15, 60, and 180 minutes after a single oral dose of captopril (6.25 mg in patients with congestive heart failure and 25 mg in controls). Despite a marked decrease in blood pressure, cerebral blood flow increased slightly in the patients with severe congestive heart failure. When a correction was applied to take account of a change in arterial carbon dioxide tension, however, cerebral blood flow was unchanged after captopril administration even in patients with the greatest decrease in blood pressure, in whom a decrease in cerebral blood flow might have been expected. In the controls, blood pressure was little affected by captopril, whereas a slight, but not statistically significant, decrease in cerebral blood flow was observed. The cerebral venous oxygen tension decreased concomitantly.

References (8)

Criteria Committee of the New York Heart Association
Nomenclature and criteria for diagnosis of disease of the heart and great vessels
(1973)
EM Stokely et al.
A single photon dynamic computer assisted tomograph (DCAT) for imaging brain function in multiple cross sections
J Comput Assist Tomogr
(1980)
NA Lassen et al.
Regional cerebral blood flow in stroke by ¹³³Xenon inhalation and emission tomography
Stroke
(1981)
OB Paulson et al.
Influence of carbon monoxide and of hemodilution on cerebral blood flow and blood gases in man
J Appl Physiol
(1973)

There are more references available in the full text version of this article.

Cited by (83)

Interactions between nanoparticles and pathological changes of vascular in Alzheimer's disease
2024, Advanced Drug Delivery Reviews
Emerging evidence suggests that vascular pathological changes play a pivotal role in the pathogenesis of Alzheimer's disease (AD). The dysfunction of the cerebral vasculature occurs in the early course of AD, characterized by alterations in vascular morphology, diminished cerebral blood flow (CBF), impairment of the neurovascular unit (NVU), vasculature inflammation, and cerebral amyloid angiopathy. Vascular dysfunction not only facilitates the influx of neurotoxic substances into the brain, triggering inflammation and immune responses but also hampers the efflux of toxic proteins such as Aβ from the brain, thereby contributing to neurodegenerative changes in AD. Furthermore, these vascular changes significantly impact drug delivery and distribution within the brain. Therefore, developing targeted delivery systems or therapeutic strategies based on vascular alterations may potentially represent a novel breakthrough in AD treatment. This review comprehensively examines various aspects of vascular alterations in AD and outlines the current interactions between nanoparticles and pathological changes of vascular.
ACE inhibitors and their interaction with systems and molecules involved in metabolism
2024, Heliyon
The main function of the renin-angiotensin-aldosterone system (RAAS) is the regulation of blood pressure; therefore, researchers have focused on its study to treat cardiovascular and renal diseases. One of the most widely used treatments derived from the study of RAAS, is the use of angiotensin-converting enzyme inhibitors (ACEi). Since it was discovered, the main target of ACEi has been the cardiovascular and renal systems. However, being the RAAS expressed locally in several specialized tissues and cells such as pneumocytes, hepatocytes, spleenocytes, enterocytes, adipocytes, and neurons the effect of inhibitors has expanded, because it is expected that RAAS has a role in the specific function of those cells. Many chronic degenerative diseases compromise the correct function of those organs, and in most of them, the RAAS is overactivated. Therefore, the use of ACEi must exert a benefit on an impaired system. Accordingly, the objective of this review is to present a brief overview of the cardiovascular and renal actions of ACEi and its effects in organs that are not the classic targets of ACEi that carry on glucose and lipid metabolism.
Angiotensin converting enzyme inhibition improves cerebrovascular control during exercise in male rats with heart failure
2021, Respiratory Physiology and Neurobiology
Citation Excerpt :
Moreover, chronic use of ACE inhibitors in HF improves quality of life (Konstam et al., 2005), all-cause mortality (Pitt et al., 2000; Yusuf et al., 1991), and exercise tolerance (Drexler et al., 1989; Kinugawa et al., 2002). Furthermore, chronic ACE inhibition in HF improves cerebral BF and VC, at least at rest (Dzau et al., 1980; Kamishirado et al., 1997; Paulson et al., 1984; Rajagopalan et al., 1984), and enhances muscle BF and VC during submaximal exercise (Drexler et al., 1989). Whether chronic ACE inhibition improves cerebral BF and VC during submaximal exercise, however, is unknown.
We investigated the effects of chronic (∼7 weeks) treatment with the angiotensin converting enzyme (ACE) inhibitor Captopril in rats with heart failure with reduced ejection fraction (HF-rEF) on brain blood flow (BF; radiolabeled microspheres) at rest and during submaximal exercise. We hypothesized that middle cerebral, posterior cerebral, and cerebellar BF during submaximal exercise (20 m/min, 5% incline) would be reduced in rats with HF-rEF (n = 10) compared to healthy (SHAM, n = 10) controls and HF-rEF rats chronically treated with Captopril (HF-rEF + Cap., n = 20). During submaximal exercise middle cerebral (HF-rEF + Cap.: 274 ± 12; HF-rEF: 234 ± 23; SHAM: 248 ± 24 ml/min/100 g) and cerebellar (HF-rEF + Cap.: 222 ± 14; HF-rEF: 243 ± 22; SHAM: 214 ± 23 ml/min/100 g) BF increased from rest in all groups with no difference among groups (P > 0.24). Posterior cerebral BF increased from rest in all groups but was lower than SHAM (394 ± 46 ml/min/100 g; P = 0.03) in HF-rEF (298 ± 19 ml/min/100 g) but not HF-rEF + Cap. (356 ± 18 ml/min/100 g; P = 0.14), supporting the concept that ACE inhibition in HF-rEF elevates brain BF increases, at least to the posterior cerebral region, during moderate intensity exercise/physical activity.
The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint
2014, Nutrition, Metabolism and Cardiovascular Diseases
Citation Excerpt :
However, the apparently opposed effects of intensive BP controls on the risk of myocardial infarction and stroke are interesting and not entirely unexpected. In fact, while the excessive reduction of systolic BP in patients with prior coronary disease may be associated with an increased risk of myocardial infarction secondary to hypoperfusion [38], the most efficient cerebral autoregulation allows an adequate perfusion even in the presence of the lowest BP values [39]. This hypothesis is confirmed by the results of PROGRESS (Perindopril Protection Against Recurrent Stroke Study) showing, in stroke survivors, a progressive reduction of recurrent ischaemic strokes and haemorrhages due to systolic BP < 115 mm Hg, with no evidence of a ‘J-shaped curve phenomenon’ [40].
Type 2 diabetes mellitus (T2DM) and essential hypertension are often associated, and retrospective data analyses suggest an association between lower blood pressure (BP) values and lower cardiovascular (CV) risk in patients with T2DM. However, the most recent intervention trials fail to demonstrate a further CV risk reduction, for BP levels <130/80 mm Hg, when compared to levels <140/90 mm Hg. Moreover, a J-shaped, rather than a linear, relationship of BP reduction with incident CV events has been strongly suggested. We here debate the main available evidences for and against the concept of ‘the lower the better’, in the light of the main intervention trials and meta-analyses, with a particular emphasis on the targets to be pursued in elderly patients. Finally, the most recent guidelines of the scientific societies are critically discussed.
The journey of the frail older adult with heart failure: Implications for management and health care systems
2014, Reviews in Clinical Gerontology
Ace Inhibitors and Their Interaction with Systems and Molecules Involved in Metabolism
2023, SSRN

View all citing articles on Scopus

¹: From the Department of Neurology, Rigshospitalet, and Department, Herlev Hospital, Copenhagan, Denmark.

View full text

Cerebral blood flow in patients with congestive heart failure treated with captopril

Abstract

Nomenclature and criteria for diagnosis of disease of the heart and great vessels

A single photon dynamic computer assisted tomograph (DCAT) for imaging brain function in multiple cross sections

J Comput Assist Tomogr

Regional cerebral blood flow in stroke by 133Xenon inhalation and emission tomography

Stroke

Influence of carbon monoxide and of hemodilution on cerebral blood flow and blood gases in man

J Appl Physiol

Regional cerebral blood flow in stroke by ¹³³Xenon inhalation and emission tomography